Phylogeny and drug resistance of HIV PR gene among HIV patients receiving RT inhibitors in Iran | Zendy

Kazem Baesi | Zendy; Majedeh Moradbeigi | Zendy; Mehrdad Ravanshad | Zendy; Ashrafolnesa Baghban | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Phylogeny and drug resistance of HIV PR gene among HIV patients receiving RT inhibitors in Iran

Author(s) -

Kazem Baesi,

Majedeh Moradbeigi,

Mehrdad Ravanshad,

Ashrafolnesa Baghban

Publication year - 2016

Publication title -

asian pacific journal of tropical biomedicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.507

H-Index - 61

eISSN - 2588-9222

pISSN - 2221-1691

DOI - 10.1016/j.apjtb.2015.12.020

Subject(s) - reverse transcriptase , drug resistance , medicine , drug , virology , protease , hiv drug resistance , transmission (telecommunications) , human immunodeficiency virus (hiv) , lentivirus , gene , biology , polymerase chain reaction , antiretroviral therapy , viral disease , pharmacology , viral load , enzyme , genetics , biochemistry , electrical engineering , engineering

Objective: To survey the level and patterns of reverse transcriptase-based drug resistance and subtype distribution among antiretroviral-treated HIV-infected patients receiving only reverse transcriptase inhibitors in Iran.Methods: A total of 25 samples of antiretroviral therapy experienced patients with no history of using protease inhibitors were collected. After RNA extraction, reverse transcriptase-nested PCR was performed. The final products were sequenced and then analysed for drug-resistant mutations and subtypes.Results: No drug resistant mutations were observed among the 25 subjects. The results showed the following subtypes among patients: CRF 35_AD (88%), CRF 28_BF (8%), and CRF 29_BF (4%).Conclusions: A significant increase in drug resistance has been noted in recently-infected patients worldwide. Subtype distributions are needed to perform properly-designed surveillance studies to continuously monitor rates and patterns of transmitted drug resistance and subtypes to help guide therapeutic approaches and limit transmission of these variants

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research